



EGIR Study Group Annual Webinar

"Hyperinsulinemia in Metabolic Diseases: Impact of Secretion, Clearance, and Homeostasis".

Monday 13 – Tuesday 14 November 2023

4:00 pm to 7:00 pm CET (Rome)

DAY 1 - Monday 13 November

4:00 pm Welcome

Abstract presentations

4:00 Cardiometabolic, cancer and health consequences of polycystic ovary syndrome (PCOS) are influenced by disease phenotype: analysis using prospective cohort and multi-organ imaging data from the UK Biobank- **Alex E Henney et al**, Department of Cardiovascular & Metabolic Medicine, University of Liverpool, Liverpool, UK

4:15 Alterations in adipose tissue distribution, cell morphology and endocrine function in youths with obesity and primary insulin hypersecretion - **Trico et al**, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

4:30 Treatment with GLP-1 receptor agonist improved mainly postprandial lipidomic profile in individuals with severe obesity and normoglycemia, despite significant weight loss - **Giuseppe Della Pepa et al**, National Research Council (CNR), Institute of Clinical Physiology (IFC), Pisa, Italy

4:45 Metabolic Effects of Sodium-Glucose-Co-Transporter-4 (SGLT4) Inhibition: From Mouse Studies to Clinical Translation -**María Moreno-López et al**, Univ. Lille, CHU Lille, Institut Pasteur Lille, Inserm UMR1190 - EGID, Lille, France

5:00-7:00 pm Keynote presentations

5:00 **Andrea Mari** - Insulin secretion and the incretin effect: a journey from physiology to treatments.

5:30 **Marzieh Salehi** – Adaptation of proglucagon-derived peptides to rerouted gut after bariatric surgery

6:00 **Chiara Saponaro** - The incretin effects on glucose-stimulated insulin secretion in human pancreatic islets

6:30 Panel Discussions



EGIR Study Group Annual Webinar

"Hyperinsulinemia in Metabolic Diseases: Impact of Secretion, Clearance, and Homeostasis".

Monday 13 – Tuesday 14 November 2023

4:00 pm to 7:00 pm CET (Rome)

DAY 2 - Tuesday 14 November

4:00pm Welcome

Abstract presentations

- 4:00 Metabolic effects of early time-restricted carbohydrate consumption vs Mediterranean diet in free-living people with type 2 diabetes - **Noemi Cimbalo et al**, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- 4:15 MASLD is a night-time disease driven by nocturnal hepatic, adipose, and skeletal muscle insulin resistance and inappropriate insulin clearance - **Thomas Marjot et al**, Oxford Centre for Diabetes, Endocrinology & Metabolism, Churchill Hospital, University of Oxford, UK
- 4:30 Increased endogenous glucose production in individuals with MASLD is associated to elevated insulin resistance, even in absence of type 2 diabetes - **Silvia Sabatini et al**, Cardiometabolic Risk Unit, Institute of Clinical Physiology, CNR, 56121 Pisa, Italy
- 4:45 Insulin resistance causes alterations in postprandial insulin clearance after ingestion of a mixed-macronutrient meal - **Kieran Smith**, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, University of Oxford, UK.

5:00-7:00 pm Keynote presentations

- 5:00 **Amalia Gastaldelli** - Insulin Clearance in Obesity, Diabetes and MASLD
- 5:30 **Paula Macedo** - Role of Insulin Degrading Enzyme in Insulin Clearance and Liver Metabolism
- 6:00 **Sonia Najjar** - Role of Hepatic Insulin Clearance in Insulin Action
- 6:30 Panel Discussions